ISSN 1662-4009 (online)

ey0018.8-9 | Clinical Trials – New Treatments | ESPEYB18

8.9. Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase

R Pivonello , M Fleseriu , J Newell-Price , X Bertagna , J Findling , A Shimatsu , F Gu , R Auchus , R Leelawattana , EJ Lee , JH Kim , A Lacroix , A Laplanche , P O'Connell , L Tauchmanova , AM Pedroncelli , BMK Biller

Lancet Diabetes Endocrinol. 2020; 8(9): 748–761.https://pubmed.ncbi.nlm.nih.gov/32730798/The authors report the outcomes from the pivotal phase 3 trial in patients with Cushing’s disease of osilodrostat (a potent oral inhibitor of cytochrome P450 11B1, [mitochondrial 11β-hydroxylase]). Twice-daily osilodrostat rapidly reduced mean 24-h urine free cortisol (UFC) and sustained ...

ey0019.6-3 | Co-morbidities associated with DSD | ESPEYB19

6.3. Vascular dysfunction and increased cardiovascular risk in hypospadias

AK Lucas-Herald , AC Montezano , R Alves-Lopes , L Haddow , M Alimussina , S O'Toole , M Flett , B Lee , SB Amjad , M Steven , K Brooksbank , L McCallum , C Delles , S Padmanabhan , SF Ahmed , RM Touyz

Eur Heart J. 2022 Mar 17:ehac112. PMID: 35296881, doi: 10.1093/eurheartj/ehac112.Brief Summary: This translational study explored the molecular and cellular mechanisms whereby testosterone impacts vascular function. The findings suggest that hypospadias is associated with vascular dysfunction and represents a risk factor for hypertension and cardiovascular disease in adulthood due to impair...

ey0016.1-6 | New Mechanisms | ESPEYB16

1.6. Regulation of feeding by somatostatin neurons in the tuberal nucleus

SX Luo , J Huang , Q Li , H Mohammad , CY Lee , K Krishna , AM Kok , YL Tan , JY Lim , H Li , LY Yeow , J Sun , M He , J Grandjean , S Sajikumar , W Han , Y Fu

To read the full abstract: Science 2018;361:76–81.The tuberal nucleus (TN) is a hypothalamic region which is well described in humans but remains poorly defined in rodents. In this paper, the authors demonstrated by specific and sophisticated techniques the role of somatostatin expressing TN (TNSST) neurons in the control of food intake in mice. Interestingly, their resul...

ey0016.12-13 | Lipid Metabolism | ESPEYB16

12.13. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer

JE Manson , NR Cook , IM Lee , W Christen , SS Bassuk , S Mora , H Gibson , CM Albert , D Gordon , T Copeland , D D'Agostino , G Friedenberg , C Ridge , V Bubes , EL Giovannucci , WC Willett , JE Buring , VITAL Research Group Buring

To read the full abstract: N Engl J Med 2019;380:23-32.Summary: In this randomized primary prevention placebo-controlled trial of 25,871 US adults, with a two-by-two factorial design, supplements with omega-3 did not lower the overall incidence of adverse cardiovascular events or cancer compared to a placebo.Comment: Omega-3 fatty acids are polyun...

ey0016.15-2 | (1) | ESPEYB16

15.2. Vitamin D supplements and prevention of cancer and cardiovascular disease

JE Manson , NR Cook , IM Lee , W Christen , SS Bassuk , S Mora , H Gibson , D Gordon , T Copeland , D D'Agostino , G Friedenberg , C Ridge , V Bubes , EL Giovannucci , WC Willett , JE Buring

To read the full abstract: N Engl J Med 2019;380:33–44This paper describes a large randomized, placebo-controlled trial of vitamin D3 (cholecalciferol) 2000 IU per day in 25,871 US adults. After median follow-up of 5.3 years, supplementation with vitamin D did not alter the risk of the primary end points, invasive cancer of any type hazard ratio, 0.96; 95% confidence interval [CI], ...

ey0020.8-13 | New Mechanisms | ESPEYB20

8.13. Low-dose IL-2 reduces IL-21(+) T cell frequency and induces anti-inflammatory gene expression in type 1 diabetes

JY Zhang , F Hamey , D Trzupek , M Mickunas , M Lee , L Godfrey , JHM Yang , ML Pekalski , J Kennet , F Waldron-Lynch , ML Evans , TIM Tree , LS Wicker , JA Todd , RC Ferreira

Brief summary: This study used high-resolution single-cell multiomics and flow cytometry on blood samples from patients with type 1 diabetes (T1D) to examine the effects of low-dose recombinant IL-2 (iLD-IL-2). Administration of iLD-IL-2 expanded thymic-derived FOXP3+HELIOS+ Tregs and CD56bright NK cells, reduced frequency of IL-21-producing CD4+T cells, and induced long-lived anti-inflammatory transcriptional changes in all T and NK...

ey0018.14-11 | (1) | ESPEYB18

14.11. Ageing hallmarks exhibit organ-specific temporal signatures

Schaum Nicholas , Lehallier Benoit , Hahn Oliver , Palovics Robert , Hosseinzadeh Shayan , Lee Song E , Sit Rene , Lee Davis P , Losada Patricia Moran , Zardeneta Macy E , Fehlmann Tobias , Webber James T , McGeever Aaron , Calcuttawala Kruti , Zhang Hui , Berdnik Daniela , Mathur Vidhu , Tan Weilun , Zee Alexander , Tan Michelle , The Tabula Muris Consortium , Pisco Angela Oliveira , Karkanias Jim , Neff Norma F , Keller Andreas , Darmanis Spyros , Quake Stephen R , Wyss-Coray Tony

Nature 2020; 583: 596–602https://www.nature.com/articles/s41586-020-2499-yIn order to understand the cellular processes that underlie ageing, the authors performed plasma proteomics at 10 different ages across the lifespan of the mouse. They integrated these data with a parallel large study published alongside this paper in the same edition (1), which describes the ‘Mouse ...

ey0019.5-1 | Novel treatments for rare skeletal disorders | ESPEYB19

5.1. Targeting TGF-β for treatment of osteogenesis imperfecta

IW Song , SC Nagamani , D Nguyen , I Grafe , VR Sutton , FH Gannon , E Munivez , MM Jiang , A Tran , M Wallace , P Esposito , S Musaad , E Strudthoff , S McGuire , M Thornton , V Shenava , S Rosenfeld , S Huang , R Shypailo , E Orwoll , B Lee

J Clin Invest. 2022 Apr 1;132(7):e152571. doi: 10.1172/JCI152571.Abstract: https://pubmed-ncbi-nlm-nih-gov.proxy.kib.ki.se/35113812/In brief: Currently, there is no disease-specific therapy for osteogenesis imperfecta (OI) where most children, of all forms of OI, with significant fracture history, are managed by bisphosphonates...

ey0019.15-10 | Assorted Conditions | ESPEYB19

15.10. Metabolomic profiling reveals extensive adrenal suppression due to inhaled corticosteroid therapy in asthma

P Kachroo , ID Stewart , RS Kelly , M Stav , K Mendez , A Dahlin , DI Soeteman , SH Chu , M Huang , M Cote , HM Knilhtila , K Lee-Sarwar , M McGeachie , A Wang , AC Wu , Y Virkud , P Zhang , NJ Wareham , EW Karlson , CE Wheelock , C Clish , ST Weiss , C Langenberg , JA Lasky-Su

Nat Med. 2022;28(4):814-22. doi: 10.1038/s41591-022-01714-5.PubMed ID: 35314841Brief summary: This study performed large-scale metabolomic profiling across 14 000 adults from 4 cohorts and identified 17 steroid metabolites whose levels were reduced in individuals with prevalent asthma. The largest reductions were associated with inhaled corticosteroid (ICS) treatment, and these were valida...

ey0017.2-3 | Neonatal Hypoglycaemia | ESPEYB17

2.3. Lower versus traditional treatment threshold for neonatal hypoglycemia

AAMW van Kempen , PF Eskes , DHGM1 Nuytemans , JH van der Lee , LM Dijksman , NR van Veenendaal , FJPCM van der Hulst , RMJ Moonen , LJI Zimmermann , EP van’t Verlaat , Baal M van Dongen-van , BA Semmekrot , HG Stas , RHT van Beek , JJ Vlietman , PH Dijk , JUM Termote , RCJ de Jonge , AC de Mol , MWA Huysman , JH Kok , M Offringa , N; HypoEXIT Study Group Boluyt

To read the full abstract: N Engl J Med. 2020 Feb 6;382(6):534–544. PMID: 32023373Neonatal hypoglycaemia is one of the most common biochemical findings in the newborn period and is an important cause of brain injury. However, despite being so common there is no consensus regarding the glucose threshold concentration at which treatment for asymptomatic neonatal hypoglycemia sho...